 |
|
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Ji Hee Yu, So Young Park, Da Young Lee, Nan Hee Kim, Ji A Seo
Kidney Res Clin Pract. 2022;41(2):136-149. Published online 2022 Mar 25 DOI: https://doi.org/10.23876/j.krcp.22.001
|
|
Citations to this article as recorded by
 Management of Elderly Patients with Chronic Kidney Disease
Yohan Park, Won Min Hwang
Yonsei Medical Journal.2025;[Epub] CrossRef Interactions between antidiabetes medications and heart–brain axis
Leong Tung Ong, Ching-Hui Sia
Current Opinion in Endocrinology, Diabetes & Obesity.2025; 32(1): 34. CrossRef Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials
Yuxin Zhang, Zhaoji Li, Yongchen Hao
European Journal of Medical Research.2025;[Epub] CrossRef Diabetic kidney disease in type 1 diabetes: challenges and differences from type 2 diabetes
Djordje S. Popovic, Dimitrios Patoulias, Luigi Gnudi, Christos S. Mantzoros
Metabolism.2024; 151: 155763. CrossRef Moderator's view: after SGLT2i and MRA antagonists, where do we go?
Carmine Zoccali, Jürgen Floege
Clinical Kidney Journal.2024;[Epub] CrossRef Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Xin‐Hui Pan, Bryan Tan, Yip Han Chin, Ethan Cheng Zhe Lee, Gwyneth Kong, Bryan Chong, Martin Kueh, Chin Meng Khoo, Anurag Mehta, Priyanka Majety, Gowtham R. Grandhi, Georgios K. Dimitriadis, Roger Foo, Nicholas W. S. Chew, Carel W. Le Roux, Mamas A. Mamas
Obesity.2024; 32(5): 840. CrossRef Fasting GLP-1 Levels and Albuminuria Are Negatively Associated in Patients with Type 2 Diabetes Mellitus
Cheol-Won Jang, Tae Yang Yu, Jin Woo Jeong, Se Eun Ha, Rajan Singh, Moon Young Lee, Seungil Ro
Journal of Personalized Medicine.2024; 14(3): 280. CrossRef Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease
Merita Rroji, Goce Spasovski
Biomedicines.2024; 12(3): 657. CrossRef Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease
Nejc Piko, Sebastjan Bevc, Radovan Hojs, Robert Ekart
Pharmaceuticals.2024; 17(4): 418. CrossRef Incretin and glucagon receptor polypharmacology in chronic kidney disease
Brandon E. McFarlin, Kevin L. Duffin, Anish Konkar
American Journal of Physiology-Endocrinology and Metabolism.2024; 326(6): E747. CrossRef Targeting Pharmacotherapies for Inflammatory and Cardiorenal Endpoints in Kidney Disease
Daniel M. Huck, Leo F. Buckley, Anil Chandraker, Ron Blankstein, Brittany Weber
Journal of Cardiovascular Pharmacology.2024; 83(6): 511. CrossRef Mechanistic Pathways and Clinical Implications of GLP-1 Receptor Agonists in Type 1 Diabetes Management
Charlotte Delrue, Marijn M. Speeckaert
International Journal of Molecular Sciences.2024; 25(17): 9351. CrossRef Effect of semaglutide on kidney function across different levels of baseline HbA1c, blood pressure, body weight and albuminuria in SUSTAIN 6 and PIONEER 6
Ellen M Apperloo, David Z I Cherney, Anja Birk Kuhlman, Johannes F E Mann, Søren Rasmussen, Peter Rossing, Katherine R Tuttle, Blaz Vrhnjak, Hiddo J L Heerspink
Nephrology Dialysis Transplantation.2024;[Epub] CrossRef From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists
Bhavarth P. Dave, Mehul R. Chorawala, Ishika V. Shah, Nidhi N. Shah, Shivam U. Bhagat, Bhupendra G. Prajapati, Pratik C. Thakkar
Molecular Biology Reports.2024;[Epub] CrossRef Metabolic Analysis and Renal Protective Effects of Linagliptin and Empagliflozin in Alport Syndrome
Mengyuan Ge, Judith Molina, Ian Tamayo, Guanshi Zhang, Jin-Ju Kim, Rachel Njeim, Flavia Fontanesi, Michael Paul Pieper, Sandra Merscher, Kumar Sharma, Alessia Fornoni
Kidney360.2024; 5(7): 1002. CrossRef Renal Reinforcements
Robert L. Thomas, Dena E. Rifkin
Journal of the American Society of Nephrology.2024; 35(9): 1143. CrossRef Renoprotective Effects of Metabolic Surgery Versus GLP1 Receptor Agonists on Progression of Kidney Impairment in Patients with Established Kidney Disease
Ali Aminian, Hamlet Gasoyan, Alexander Zajichek, Mohammad Hesam Alavi, Nicholas J. Casacchia, Rickesha Wilson, Xiaoxi Feng, Ricard Corcelles, Stacy A. Brethauer, Philip R. Schauer, Matthew Kroh, Raul J. Rosenthal, Jonathan J. Taliercio, Emilio D. Poggio,
Annals of Surgery.2024;[Epub] CrossRef Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes
Lidiya Kukova, Kashif M. Munir, Ahmed Sayeed, Stephen N. Davis
Expert Opinion on Drug Metabolism & Toxicology.2024; 20(10): 939. CrossRef Tirzepatide Prescribing Practices and Efficacy in Patients with Diabetes and Chronic Kidney Disease at a Large Tertiary Care Center in the United States
Sriya Kosaraju, Rong Zhang
Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 3621. CrossRef Exploring the clinical effectiveness of glucagon-like peptide-1 receptor agonists in managing cardiovascular complications: an updated comprehensive review and future directives
Nandan Joshi, Muhammad Zohaib Qasim, Srilakshmidevi Kanumilli, Faiza Shaukat, Ateesh Kumar, Fnu Mahek, Saif Khalid, Mohd Zeeshan, Mahboob Younus Shaik, Syeed Mahmud Nishat, Fenil Gandhi, Christopher Belletieri
Annals of Medicine & Surgery.2024; 86(10): 5947. CrossRef Exploring Adiposity and Chronic Kidney Disease: Clinical Implications, Management Strategies, Prognostic Considerations
Lasin Ozbek, Sama Mahmoud Abdel-Rahman, Selen Unlu, Mustafa Guldan, Sidar Copur, Alexandru Burlacu, Adrian Covic, Mehmet Kanbay
Medicina.2024; 60(10): 1668. CrossRef Effect of GLP-1 Receptor Agonists on Renal Functions and Diabetic Nephropathy in Type 2 Diabetes Mellitus (T2DM) Patients: A Systematic Review and Meta-Analysis
Ali J Mohamed, Ali H AlSaffar, Ali A Mohamed , Mohamed H Khamis, Ahmed A Khalaf, Husain J AlAradi, Abdulla I Abuhamaid, Ali H Sanad, Hasan L Abbas, Abdulla M Abdulla, Osama A Alkhamis
Cureus.2024;[Epub] CrossRef GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction
Giovanni Battista Bonfioli, Luca Rodella, Marco Metra, Enrico Vizzardi
Heart Failure Reviews.2024; 30(1): 131. CrossRef Glucagon-like peptide-1 agonists in cardiovascular diseases: a bibliometric analysis from inception to 2023
Abinash Mahapatro, Ali Bozorgi, Sri U.J. Obulareddy, Shika M. Jain, Rohan Reddy Korsapati, Aroon Kumar, Kristina Patel, Saman Soltani Moghadam, Arash Arya, Abdulhadi Jameel Alotaibi, Mohammad-Hossein Keivanlou, Soheil Hassanipour, Maryam Hasanpour, Ehsan
Annals of Medicine & Surgery.2024; 86(11): 6602. CrossRef GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?
Georgia Doumani, Panagiotis Theofilis, Vasilis Tsimihodimos, Rigas G. Kalaitzidis
Life.2024; 14(11): 1478. CrossRef The Inappropriate Use of GLP-1 Analogs: Reflections from Pharmacoepidemiology
Sofía Echeverry-Guerrero, Salomé González-Vélez, Ana-Sofía Arévalo-Lara, Juan-Camilo Calvache-Orozco, Sebastián Kurt Villarroel-Hagemann, Luis Carlos Rojas-Rodríguez, Andrés M. Pérez-Acosta, Carlos-Alberto Calderon-Ospina
Pharmacoepidemiology.2024; 3(4): 365. CrossRef Cardiovascular Disease in Patients with Chronic Kidney Disease: Current Understanding, Preventative Strategies, and Future Directions
Robert Naami, Drew M. Miller, Sanjana Datla, Mahboob Rahman, Sadeer Al-Kindi, Ian J. Neeland
Cardiology in Review.2024;[Epub] CrossRef Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side
Aly M. Abdelrahman, Alaa S. Awad, Irtiza Hasan, Emaad M. Abdel-Rahman
Journal of Clinical Medicine.2024; 13(24): 7732. CrossRef A New Era in Diabetic Kidney Disease Treatment: The Four Pillars and Strategies to Build Beyond
Sangyub Han, Sejoong Kim
Electrolytes & Blood Pressure.2024; 22(2): 21. CrossRef Management Strategies for Potassium Levels During Non-steroidal Mineralocorticoid Receptor Antagonist Therapy: A Comprehensive Review
Hyung Eun Son
Electrolytes & Blood Pressure.2024; 22(2): 29. CrossRef The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes
Jessica Kearney, Luigi Gnudi
Pharmaceutics.2023; 15(5): 1343. CrossRef Obesity-related hypertension and chronic kidney disease: from evaluation to management
Mi-Hyang Jung, Sang-Hyun Ihm
Kidney Research and Clinical Practice.2023; 42(4): 431. CrossRef An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review
Marah Alsayed Hasan, Stanley Schwartz, Victoria McKenna, Richard Ing
Obesity Surgery.2023; 33(9): 2927. CrossRef Kidney Considerations in Pediatric Obesity
Alexandra Sawyer, Evan Zeitler, Howard Trachtman, Petter Bjornstad
Current Obesity Reports.2023; 12(3): 332. CrossRef Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review
Sandra Martínez-Hernández, Martín Muñoz-Ortega, Manuel Ávila-Blanco, Mariana Medina-Pizaño, Javier Ventura-Juárez
Biomedicines.2023; 11(10): 2828. CrossRef The benefits of GLP1 receptors in cardiovascular diseases
Lamija Ferhatbegović, Denis Mršić, Amra Macić-Džanković
Frontiers in Clinical Diabetes and Healthcare.2023;[Epub] CrossRef Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease
Sungmin Kim, Jung Nam An, Young Rim Song, Sung Gyun Kim, Hyung Seok Lee, AJin Cho, Jwa-Kyung Kim, Tomislav Bulum
PLOS ONE.2022; 17(8): e0273004. CrossRef
|